Codis
Private Company
Funding information not available
Overview
Codis is a specialized CDMO focused on advanced particle engineering and commercial-scale spray drying to enhance drug solubility and manufacturability. Leveraging a 30-year regulatory track record and over 400,000 square feet of manufacturing space, it provides end-to-end services from formulation development to final dosage forms for a global client base. Its core value proposition lies in solving complex bioavailability challenges through technologies like amorphous solid dispersions and microencapsulation, positioning it as a critical partner for the commercialization of poorly soluble compounds. The company is privately held, revenue-generating, and serves a broad market from pharmaceuticals to nutraceuticals.
Technology Platform
Integrated particle engineering platform featuring commercial-scale GMP spray drying (for amorphous solid dispersions), microencapsulation via spinning disc, continuous granulation, final dosage form manufacturing, and functional excipient development.
Opportunities
Risk Factors
Competitive Landscape
Codis competes in the advanced formulation CDMO space against larger, diversified CDMOs (e.g., Lonza, Catalent) and other specialized particle engineering firms. Its differentiation lies in its claimed position as one of the largest global GMP spray drying capacities, deep expertise in amorphous solid dispersions, and a long-term commercial track record with complex molecules like Sevelamer.